Gold tier: mechanically validated evidence, with its primary source.
150 evidence items · page 3 / 6
1.14 adjusted_prevalence_ratioThe adjusted prevalence ratio for cervical cancer screening in intervention clinics compared to control clinics was 1.14 (95% CI 0.74–1.75) when adjusted for having at least one provider trained to perform cervical cancer screening at baseline.
Kenyacancer du col de l'utéruspublished 2023Implementation science : ISeurope_pmcdocument of 5 observationsDOI 10.1186/s13012-023-01322-y
7 %As of October 2021, 7% of Fahari ya Jamii project-supported HIV clinics in Nairobi and Kajiado Counties were treating visual inspection with acetic acid (VIA) positive lesions.
Kenyacancer du col de l'utérusobserved October 2021published 2025BMC women's healthPubMeddocument of 8 observations
36.4 %Thirty-six point four percent (36.4%) of the respondents obtained information about cervical cancer from media.
Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations
16,757 screeningsThere were a total of 16,757 cervical cancer screenings or rescreenings documented across the 19 study sites in Siaya and Busia counties of Kenya from September 2021 to September 2022.
Kenyacancer du col de l'utérusobserved September 2021 to September 2022published 2025JCO global oncologyPubMeddocument of 3 observations
3,000 deathsIn Kenya, over 3,000 women died from cervical cancer in 2020.
Kenyacancer du col de l'utérusobserved 2020published 2023PloS onePubMeddocument of 16 observations
2.43 aPRIn rural Kenya, microfinance members had an adjusted prevalence ratio of 2.43 for cervical cancer screening compared to non-members.
Kenyacancer du col de l'utérusobserved November 2018 to March 2019published 2020BMC health services researchPubMeddocument of 2 observations
9.5 %In Eldoret, cervical cancer incidence increased significantly by 9.5% annually from 2002 to 2016.
Kenyacancer du col de l'utérusobserved 2002-2016published 2020British journal of cancereurope_pmcdocument of 5 observations
29.4 %Cervical cancer screening uptake among women living with HIV in western Kenya was 29.4% during the study period from October 2007 to February 2019.
Kenyacancer du col de l'utérusobserved October 2007 to February 2019published 2024JCO global oncologyPubMeddocument of 6 observations
320,000 casesWe estimated 320,000 cases attributed to cervical cancer over the lifetimes of the 14 evaluated birth cohorts.
Kenyacancer du col de l'utéruspublished 2023VaccinePubMeddocument of 6 observations
50.6 yearsThe mean age at diagnosis was 50.6 years.
Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations
40 %Positive lymph nodes were the most common high-risk feature, occurring in 40.0% of HIV-negative patients.
Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations
48.6 %HPV DNA self-sampling accounted for 48.6% of cervical cancer screening tests.
Kenyacancer du col de l'utéruspublished 2026BMC cancerPubMeddocument of 12 observations
45 %The 2-year survival probability after diagnosis of cervical cancer was 45%.
Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations
1 per_317Among 317 women, invasive cervical cancer controls included HPV16 and 66 coinfection in 1/317 (0.3%).
Kenyacancer du col de l'utéruspublished 2021BioMed research internationalPubMeddocument of 9 observations
43.6 %Forty-three point six percent (41/94) of the respondents who had ever been screened perceived cervical screening procedures as uncomfortable.
Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations
9.43 hazard_rate_ratioIn patients with cervical cancer, no cancer-directed therapy was associated with substantially worse overall survival (hazard rate ratio, 9.43; 95% confidence interval, 3.03–29.33).
Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718
27 %Cervical cancer screening uptake among women living with HIV was 27.0% in the AMPATH program during the study period from October 2007 to February 2019.
Kenyacancer du col de l'utérusobserved October 2007 to February 2019published 2024JCO global oncologyPubMeddocument of 6 observations
50 %In Kenya, nearly 50% of women diagnosed with cervical cancer are diagnosed late.
Kenyacancer du col de l'utéruspublished 2026BMC research notesPubMeddocument of 7 observations
46.1 per_100000Cervical cancer had an age-standardized incidence rate (ASR) of 46.1 per 100,000 among women in Nairobi during 2004–2008.
Kenyacancer du col de l'utérusobserved 2004-2008published 2015International journal of cancereurope_pmcdocument of 9 observations
84 %Clinics that reported cervical cancer screening were much more likely to have at least one provider trained to perform cervical cancer screening (84%, 32/38) compared to clinics that did not report screening (28%, 9/32; PR 3.77, 95%CI 1.82-7.83).
Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2
16.667 %Only one in six patients with cervical cancer in sub-Saharan Africa received cancer-directed therapy with curative potential.
Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718
85 %Cervical cancer awareness was 85.0% among mothers of adolescent girls in Western Kenya.
Kenyacancer du col de l'utéruspublished 2021The Pan African medical journalPubMeddocument of 5 observations
14.5 monthsThe median overall survival was 14.5 months among people living with HIV.
Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations
46.9 %Adherence to treatment guidelines was not assessed in 46.9% of patients.
Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718
Dialogue-based educational intervention by trained community health volunteers significantly improved cervical cancer knowledge among women of reproductive age (p < 0.001).
Kenyacancer du col de l'utéruspublished 2024BMC women's healthPubMeddocument of 3 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.